Incorrect dosing and unsafe escalation Lack of support in managing side effects such as nausea, dizziness, and digestive issues Exposure to unsafe or counterfeit products While the upfront cost looks cheaper, the long-term consequences can be both unsafe and ineffective
New innovations for obesity are quickly coming to market, and the list of indications GLP-1 drugs could treat is expanding
Dosing and Administration# Liraglutide# Saxenda (obesity) : Start 0.6 mg daily, titrate weekly by 0.6 mg to 3.0 mg daily (5-week titration) Victoza (T2D) : Start 0.6 mg daily, increase to 1.2 mg, max 1.8 mg daily Subcutaneous injection, abdomen/thigh/upper arm Any time of day, with or without food No oral weight management formulation Semaglutide# Wegovy (obesity) : Start 0.25 mg weekly, titrate monthly to 2.4 mg weekly (16-week titration) Ozempic (T2D) : Start 0.25 mg weekly, titrate to 0.5 mg, max 2.0 mg weekly Rybelsus (T2D) : 3 mg daily oral for 30 days, then 7 mg, max 14 mg Oral semaglutide 25 mg (approved 2025): Oral formulation for weight management Weekly injection or daily oral tablet
Tnh trng da ph hp: Da xn mu, thm sm
Sofwave stands out because it strikes the perfect balance between results and convenience